Lilly partners with API to launch ‘Obesity Gurukul’, a flagship continuing medical education program: Our Bureau, Bengaluru Monday, July 14, 2025, 15:20 Hrs [IST] Eli Lilly an ...

The initiative will provide practical insights into understanding of obesity pathophysiology and its management.

Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

Eli Lilly and Co's obesity drug Zepbound led to greater weight loss than Novo Nordisk's Wegovy in a head-to-head Phase 3b trial, according to data published in The New England Journal of Medicine ...

In advance of CMS’ negotiated price for the blood thinner taking effect next year, partners Bristol Myers Squibb and Pfizer ...

Eli Lilly gains analyst support after Phase 3 success. ... Cantor sees Eli Lilly reaching over 85% obesity market share by 2029–2030. ... In the first Phase 3 trial of the ACHIEVE program, ...

Eli Lilly’s GLP-1 drugs face strong competition from Novo Nordisk’s NVO semaglutide products, Wegovy (obesity) and Ozempic (T2D). Like LLY, NVO is also evaluating several next-generation ...

An experimental weight-loss drug from Eli Lilly & Co. helped patients lose weight with few side effects, according to the summary of a small study that suggests the company has another foothold… ...

Lilly expects to submit the non-diabetes Phase 3 data to global regulatory agencies by the end of the year, said Ken Custer, head of cardiometabolic health at the company. Lilly said it plans to ...

People taking Eli Lilly and Co.'s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the medications.